Healthcare Industry News: Betrixaban
News Release - September 24, 2009
Portola Pharmaceuticals Announces Promotions of Senior Management TeamSOUTH SAN FRANCISCO, Calif., Sept. 24 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals, Inc. today announced executive promotions on the senior management team.
- William Lis, vice president, Business & Commercial Development, has been promoted to the newly created position of chief operating officer. In this role, he will have responsibility for Corporate Development, Clinical Development and Pharmaceutical Development.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y(12)( )ADP receptor antagonist, is licensed to Novartis. Both Betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.
Portola also has proprietary pipeline programs focused on the discovery and development of a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin, and a novel recombinant protein anticoagulant antidote to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. In addition, Portola is building a kinase program based on novel, specific Syk and JAK inhibitors to treat inflammatory diseases. For additional information, visit www.portola.com.
Source: Portola Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsU.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa(R) for Third Year
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors